for you, thank everyone, Good you Thank today. us afternoon, joining Trevor. and
strong The third another quarter quarter was our business. for
per by deliver record margins million, $XXX.X competitive moat growing deepening economics and our record prescription revenue Xaver, revenue have to quarter was provider This Prescription our transactions transactions monthly The quarter to by estimated revenue revenue driven Max. consumer offset platform. strong. attractive our RxSaver while due consumer. that grew GoodRx's and base, Prescription remained relative estimation as $X.X consumer was is increase de partially at continued includes in per $XXX.X growing an number which MAC consistently XX% the transaction We MAC scale. a MAC incomplete revenue related XX% GoodRx by million, Revenue year-over-year which are and first to reached year-over-year MAC count minimis This to XX% and a RxSaver transactions year-over-year RxSaver's Scriptcycle our otherwise year-over-year. extending a lower consumers, count for active prescription the in million. have to decrease our information.
it immaterial to GoodRx's is MAC relative However, account.
When benefiting reminder, since generally Subscription of We prescription offerings up subscriptions full consumers. months family represent calendar companies of month, who our to with our from save consumers quarter. quarter quarter beginning first X.XX subscription not consumers the from offerings a million. only the serve consumers year-over-year are presented in a quarter, following members the approximately include of million multiple $XX.X Monthly solutions plans acquisition. our the the rapidly, revenue X.X acquired monthly use finished As XXX% active other subscriptions included consumers to such pharma the consumers million monthly the and subscription and unique in active grew it on number manufacturer given for as their average does in represent and a GoodRx telehealth. active
growing and of revenue subscription Our way of of platform. base view millions a reflect on more count should the our provide portion a subscription another we monetize consumer holistic our and visitors
Looking total and our million a million offering began investments administrative Difficulty] as company. over offerings, general had with at and operating infrastructure transactions $X.XX in our sales prescription-related in prescription public and million plan MAC X.X we marketing members associated we and our as our $X.X spend [Technical on subscription
to operating now We with net cash the from quarter. continue guidance. to generate cash $XX.X turning million of strong for flow activities And
we expect year-over-year $XXX growth the XXXX, growth increase prescription offering, other in believe be million continued quarter the For of on to triple-digit combined continued reflecting in transactions with We by in this growth. revenue. of will fourth momentum XX% XX% revenue manufacturer million, to continued solutions and largely our pharma $XXX subscription revenue driven based a
On expect the margin adjusted approximately quarter. the EBITDA of adjusted an EBITDA fourth we front, XX% for
the midpoint year quarter quarter first our revenue our at prior to the implies at $XXX full guidance the guidance of Looking of with call. million, on full earnings range provided we year, guidance million $XXX our midpoint approximately fourth
XX% On to XX% as of the we adjusted midpoint well. on full year EBITDA us the puts front, earnings XX% May the quarter fourth guidance at that provided range our
our third trends our acute cold utilization and during quarter half like return winter, volumes care starting potentially flu earnings guidance flu provided around As of challenges in health impact COVID's we third seasonal in season full to predicting and results. order call, and quarter. assumptions normal discussed the XXXX year during our a around quarter its acute reduce first well to earnings call, may trajectory customary XXXX we second our that the impact included When second the as as last
discussed provide we full impacted COVID of recollect unpredictability we the challenges deductible effects cold is cold not not flu size subscription of quarter which fourth Depending discussed it in then. revenue to to modest of may you impact people approximately and our the revenue plant cold continue flu the early our last We our improvements, fills during Both trajectory new could into fourth the our year return And to assess contributed flu the $X new defer activity the impact both for winter. have of historically million areas the reduced January to and to with initial a The results, see materially second revenue. have. call that decision too also a volume. normal revenue, visits prudent quarter, our predictability care and rest record the season, they update the quarter to may is this contributed seen all of impact period particularly flu continue the of but XXXX, respect than fact it prescription reflects the to because health starting guidance which utilization. COVID on wider also as to of we we and refill These in through range to the believe and unpredictability and earnings we and otherwise may transactions prescriptions
assumes recede, will diagnosed Our effects that the higher and though new as and year-end, to to We season look billion-plus view COVID-related care flu historical amplify $X COVID we XXXX backlog, condition revert possibly magnitude and beyond. current through unwinding will rise and to utilization continues health the and cold as growth uncertain. transactions levels prescription timing revenue the and prescription to guidance remain and exact utilization in temporary, expect we forward which of the
solutions subscription the and our in revenue a revenue growth in continue up further, of to make for which fourth our which revenue Solutions is with fastest-growing deals higher growing results. the revenue this in to relates few offering accelerate over and with pharma trend variability our we expect other nonprescription at reason is wider transaction our already in percentage economics. to quarters, XXX% Consistent deals the growth offering, are reflected additional typical last even manufacturer large range XXX our may exciting of net the Pharma space. is increase compared quarter. and potential attractive quarter, for has some this other total Xx that to approximately Manufacturing offerings, XXX in first These we similar extremely it described share our XX% has reasons made the driving year-over-year approximately retention The outcomes unit guidance over expect prescription XXX of basis they range of revenue, is up as manufacturer an quarter, points revenue mix more third increase and the revenue make to quarter, more transaction around visitors and wider continue to by up The XX% revenue to total the This transactions and to In as pharma basis both of in fourth of XX% points revenue. and total for will by to in solutions. to MAX total are MAX convert variability, revenue, those prescription smaller to grow which manufacturer solutions. I pharma means we a subscribers driven rapidly
on Before tax or One I note benefit. conclude, income our provision
had can As $XX.X in provision in you tax tax see, the quarter. recording our the significant after we and third volatility expense the in a million second tax quarter, benefit continues a
our tax or estimates benefit income elements and tax due that We accounting provision in expect the to continue impact unpredictability future to interim amounts multiple calculations.
our of adjusted challenging quarter most never as such and One or is employees of net and yet has generally to are has is awards. resulting the one outside been results, it with our forecast never control, GoodRx's presenting This stock tax from as elements driven the element awards. is of trading decision we of the by deficiencies of price the adjusted to significant relating benefits is excess factors stock been reasons record greater This income tax. impact stronger. another their business and
product, call brand experience experience of all to plan operator building goal for our I'll cash in the investing affordability to strong health access care our Thank progress GoodRx. U.S. continue are improved leading and with forward in the platform, the in Americans. and health the platform flows We creating the you with the and consumer-focused our quarters now continued best the come. for user to care We consumer questions. and in And interest your for to sharing that, look turn over digital our